 |
|
Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
Saba Sayari, Hassan Neishaboori, Maryam Jameshorani
Clin Mol Hepatol. 2018;24(3):331-338. Published online 2018 Jun 12 DOI: https://doi.org/10.3350/cmh.2018.0006
|
|
Citations to this article as recorded by
 The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Yijia Song, Sutong Liu, Lihui Zhang, Wenxia Zhao, Yuanmei Qin, Minghao Liu
Frontiers in Nutrition.2025;[Epub] CrossRef The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
Annalisa Pezzoli, Ludovico Abenavoli, Marialaura Scarcella, Carlo Rasetti, Gianluca Svegliati Baroni, Jan Tack, Emidio Scarpellini
Medicina.2025; 61(3): 387. CrossRef Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications
Farah Abdelhameed, Attia Mustafa, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Nwe Ni Than, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva
Livers.2025; 5(1): 11. CrossRef Beneficial effects of the probiotics and synbiotics supplementation on anthropometric indices and body composition in adults: A systematic review and meta‐analysis
Saeede Saadati, Kaveh Naseri, Omid Asbaghi, Mohsen Yousefi, Elnaz Golalipour, Barbora de Courten
Obesity Reviews.2024;[Epub] CrossRef Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis
Yuezhi Zhu, Jen Kit Tan, Jia Liu, Jo Aan Goon
Antioxidants.2024; 13(3): 329. CrossRef Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo
Frontiers in Nutrition.2024;[Epub] CrossRef Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis
Yafang Yang, Ligang Yang, Jiale Wu, Jing Hu, Min Wan, Jindi Bie, Jiaxin Li, Da Pan, Guiju Sun, Chao Yang
Clinical Nutrition.2024; 43(6): 1224. CrossRef Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Aakash Mantri, Anika Köhlmoos, Daniela Stephanie Schelski, Waldemar Seel, Birgit Stoffel-Wagner, Peter Krawitz, Peter Stehle, Jens Juul Holst, Bernd Weber, Leonie Koban, Hilke Plassmann, Marie-Christine Simon
Nutrients.2024; 16(9): 1300. CrossRef The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review
Azin Vakilpour, Ehsan Amini-Salehi, Arman Soltani Moghadam, Mohammad-Hossein Keivanlou, Negin Letafatkar, Arman Habibi, Mohammad Hashemi, Negar Eslami, Reza Zare, Naeim Norouzi, Hamed Delam, Farahnaz Joukar, Fariborz Mansour-Ghanaei, Soheil Hassanipour, S
Nutrition & Diabetes.2024;[Epub] CrossRef Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials
Juan Wu, Xiaoyang Chen, Jun Qian, Guochun Li
Clinics and Research in Hepatology and Gastroenterology.2024; 48(7): 102397. CrossRef Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Youwen Pan, Yafang Yang, Jiale Wu, Haiteng Zhou, Chao Yang
BMC Gastroenterology.2024;[Epub] CrossRef The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials
Vali Musazadeh, Kimia Assadian, Fatemeh Rajabi, Amir Hossein Faghfouri, Yosra Soleymani, Zeynab Kavyani, Behnam Najafiyan
Pharmacological Research.2024; 208: 107398. CrossRef Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease
Shendong Wang, Junhao Yin, Zhaojun Liu, Xin Liu, Ge Tian, Xijian Xin, Yiming Qin, Xiujing Feng
Life Sciences.2024; 359: 123211. CrossRef Gut microbiota and obesity: an overview of microbiota to microbial-based therapies
Elham Sheykhsaran, Amin Abbasi, Hamed Ebrahimzadeh Leylabadlo, Javid Sadeghi, Samaneh Mehri, Fariba Naeimi Mazraeh, Hadi Feizi, Hossein Bannazadeh Baghi
Postgraduate Medical Journal.2023; 99(1171): 384. CrossRef The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
Zhonglin Li, Hang Yuan, Huikuan Chu, Ling Yang
Microorganisms.2023; 11(8): 2059. CrossRef Effects of synbiotics supplementation on anthropometric and lipid profile parameters: Finding from an umbrella meta-analysis
Vali Musazadeh, Maryam Mohammadi Anilou, Mahdi Vajdi, Arash Karimi, Sana Sedgh Ahrabi, Parvin Dehghan
Frontiers in Nutrition.2023;[Epub] CrossRef Using synbiotics supplementation to treat hepatic steatosis: A comprehensive meta-analysis of randomized controlled trials
Ammar Nojaid, Jason William, Krisanto Tanjaya, Nurpudji Astuti Taslim, Fahrul Nurkolis
Human Nutrition & Metabolism.2023; 32: 200194. CrossRef Role of Probiotics and Gut microbiota in Liver Diseases
Safeena Beevi S S, Biju Pottakkat, Sankar Narayanan
Asian Journal of Nursing Education and Research.2023; : 157. CrossRef Effects of Synbiotic-Containing Bacillus coagulans (GBI-30) on the Cardiovascular Status of Patients With Polycystic Ovary Syndrome: A Triple-blinded, Randomized, Placebo-controlled Study
Zahra Hariri, Zahra Yari, Sedighe Hoseini, Afsaneh Mehrnami, Khadijeh Abhari, Golbon Sohrab
Clinical Therapeutics.2023; 45(10): e193. CrossRef Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease
Wenwu Huang, Boyuan Shen, Xiumei Li, Tongcun Zhang, Xiang Zhou
Foods.2023; 12(18): 3393. CrossRef Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms
Qamraa H. Alqahtani, Samiyah Alshehri, Ahlam M. Alhusaini, Wedad S. Sarawi, Sana S. Alqarni, Raessa Mohamed, Meha N. Kumar, Juman Al-Saab, Iman H. Hasan
Diseases.2023; 11(4): 184. CrossRef Inulin as a Clinical Therapeutic Intervention in Metabolic Associated Fatty Liver Disease
Varenka Barbero-Becerra, Eva Juárez-Hernández, Norberto C Chávez-Tapia, Misael Uribe
Food Reviews International.2022; 38(sup1): 336. CrossRef Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahim
Frontiers in Medicine.2022;[Epub] CrossRef The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis
Shudi Li, Jiangkai Liu, Zhen Wang, Fei Duan, Zi Jia, Xinju Chen, Suling Li
Frontiers in Public Health.2022;[Epub] CrossRef Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Yajie Fu, Yanzhi Zhou, Linhu Shen, Xuewen Li, Haorui Zhang, Yeqi Cui, Ke Zhang, Weiguo Li, Wei-dong Chen, Shizhen Zhao, Yunfu Li, Wenling Ye
Frontiers in Pharmacology.2022;[Epub] CrossRef Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec
Clinical Science.2022; 136(18): 1347. CrossRef A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
John A. Dougherty, Erenie Guirguis, Krisy-Ann Thornby
Annals of Pharmacotherapy.2021; 55(1): 65. CrossRef The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Erica Jennison, Christopher D. Byrne
Clinical and Molecular Hepatology.2021; 27(1): 22. CrossRef Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Alvaro Santos-Laso, María Gutiérrez-Larrañaga, Marta Alonso-Peña, Juan M. Medina, Paula Iruzubieta, María Teresa Arias-Loste, Marcos López-Hoyos, Javier Crespo
Biomedicines.2021; 10(1): 46. CrossRef Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Oluyemi Komolafe, Elena Buzzetti, Audrey Linden, Lawrence MJ Best, Angela M Madden, Danielle Roberts, Thomas JG Chase, Dominic Fritche, Suzanne C Freeman, Nicola J Cooper, Alex J Sutton, Elisabeth Jane Milne, Kathy Wright, Chavdar S Pavlov, Brian R Davids
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef Efficacy of synbiotic supplementation in obesity treatment: A systematic review and meta-analysis of clinical trials
Amir Hadi, Kimia Alizadeh, Hossein Hajianfar, Hamed Mohammadi, Maryam Miraghajani
Critical Reviews in Food Science and Nutrition.2020; 60(4): 584. CrossRef Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials
Amir Hadi, Ehsan Ghaedi, Saman Khalesi, Makan Pourmasoumi, Arman Arab
European Journal of Nutrition.2020; 59(7): 2857. CrossRef The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease
Chencheng Xie, Dina Halegoua-DeMarzio
Current Hepatology Reports.2020; 19(4): 420. CrossRef Gut microbiome–targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression
Suzanne R Sharpton, Bharat Maraj, Emily Harding-Theobald, Eric Vittinghoff, Norah A Terrault
The American Journal of Clinical Nutrition.2019; 110(1): 139. CrossRef Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Kenneth Cusi
Hepatology.2019; 69(6): 2318. CrossRef A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach
Abbas Ali Sangouni, Saeid Ghavamzadeh
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(5): 2917. CrossRef Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Yao Tang, Juan Huang, Wen yue Zhang, Si Qin, Yi xuan Yang, Hong Ren, Qin-bing Yang, Huaidong Hu
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Chencheng Xie, Dina Halegoua-DeMarzio
Nutrients.2019; 11(11): 2837. CrossRef Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
Yong Kyun Cho
Clinical and Molecular Hepatology.2018; 24(3): 299. CrossRef Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta
Pharmaceuticals.2018; 11(4): 121. CrossRef
|